ArticleAmerican journal of cancer research2025
Extracellular vesicle lncRNA AGAP2-AS1 as a non-invasive prognostic biomarker in patients with advanced renal cell carcinoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Unveiling the epigenetic landscape: transforming renal cell carcinoma treatment.Clinical epigenetics · 2026Review
- A new cuproptosis-associated lncRNA signature predicts the prognosis of clear cell renal cell carcinoma patients.Discover oncology · 2026Article
- Plasma exosomal lncRNA SLC16A1-AS1 as an early diagnostic biomarker for renal cell carcinoma.Frontiers in oncology · 2026Article
- Research advances in extracellular vesicles for diagnosis and treatment of genitourinary cancers.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor (ICI)-based combination therapies, such as dual ICI therapy or ICI plus vascular endothelial growth factor (VEGF) inhibitors, are recommended as first-line treatment for advanced renal cell carcinoma (aRCC). ICI-based combination therapy has improved the prognosis of patients with aRCC compared with the era of VEGF inhibitor monotherapy. Long noncoding RNAs (lncRNAs) are involved in the prognosis and metastasis of several cancers, and extracellular vesicle (EV)-derived lncRNAs play important roles in tumor progression and metastasis, serving as prognostic biomarkers. The lncRNA AGAP2-AS1 is highly expressed in RCC and is associated with poorer prognosis in patients with elevated expression levels. This study aimed to investigate the function of lncRNA AGAP2-AS1 in RCC and explore whether serum-derived EV lncRNA AGAP2-AS1 serves as a prognostic biomarker in patients with aRCC. Firstly, we examined lncRNA AGAP2-AS1 expression in RCC and normal kidney tissues with pathologically confirmed RCC at our institution. We also performed a functional analysis of lncRNA AGAP2-AS1 in RCC cell lines. Additionally, we analyzed the relationship between the EV lncRNA AGAP2-AS1 expression and the prognosis of 47 patients with aRCC treated with ICI-based combined therapy. We observed higher lncRNA AGAP2-AS1 expression in RCC tissues than in normal tissues. Furthermore, AGAP2-AS1 knockdown in RCC cells using small interfering RNA significantly decreased cell viability, invasion, and migration. Patients with progressive disease (PD) receiving ICI-based combination therapy exhibited significantly higher expression of the EV lncRNA AGAP2-AS1 than patients without PD. We then classified 47 patients into two groups by median lncRNA AGAP2-AS1 expression. Notably, the high-expression group exhibited significantly worse progression-free survival and overall survival than the low-expression group (log-rank P = 0.0193 and log-rank P = 0.0256, respectively). In multivariate analysis, high EV lncRNA AGAP2-AS1 expression was an independent risk factor for disease progression (hazard ratio = 3.6, P = 0.0287). Overall, high EV lncRNA AGAP2-AS1 expression was associated with poorer prognosis in patients with aRCC. Therefore, serum-derived EV lncRNA AGAP2-AS1 may be an effective non-invasive prognostic biomarker in patients with aRCC treated with ICI-based combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.